New regulation bans AI from replacing pharmacists in prescription review
Critical regulatory update on AI's role in healthcare: human-in-the-loop is now a legal requirement for prescription rev
30-Second TL;DR
What Changed
The new guidelines mandate that prescription reviews must be performed by licensed pharmacists, not AI.
Why It Matters
This regulation sets a legal precedent for AI in healthcare, emphasizing that while AI can assist, human accountability remains mandatory for high-risk medical decisions.
What To Do Next
If developing AI for medical diagnostics or prescription workflows, ensure your product includes a 'human-in-the-loop' architecture to meet strict regulatory compliance.
Key Points
- •The new guidelines mandate that prescription reviews must be performed by licensed pharmacists, not AI.
- •Regulators are shifting toward 'smart supervision' using AI and big data to monitor platform compliance.
- •The 'mystery shopper' mechanism is recommended to audit the entire online drug sales chain, including prescription validity.
Deep Insight
Background and context from public sources — not the original article. 13 sources cited.
Enhanced Key Takeaways
- •The new guidelines are part of a broader effort to address long-standing safety and quality risks in China's rapidly expanding online drug retail market, which exceeded 80 billion yuan ($11.8 billion) in 2025.
- •The regulation also explicitly prohibits the reuse of the same prescription for multiple purchases and requires online drug retailers to manage pharmacists' daily review workloads to prevent irrational or excessive medication use.
- •This national ban on AI in prescription review follows earlier, more localized prohibitions, such as draft rules in Beijing (August 2023) and a ban in Hunan province (February 2025), indicating a trend towards stricter human oversight in online medical services.
- •The "smart supervision" framework, led by the National Medical Products Administration (NMPA), aims to leverage AI and big data for comprehensive lifecycle oversight, including risk-based inspections, data-driven planning, and intelligent identification of compliance issues across drugs, medical devices, and cosmetics.
Future ImplicationsAI analysis grounded in cited sources
Timeline
- 2019China amended the Drug Administration Law to permit online sale of prescription drugs with limitations, marking its first national congress-level regulatory policy on online pharmacy regulation.
- 2020-04An AI-based internet hospital pharmacy service mode was launched at Eye & ENT Hospital of Fudan University, utilizing AI for prescription preview.
- 2022-12-01China's Administrative Measures for Supervising Online Sales of Drugs (Decree 58) took effect, allowing nationwide online sales of prescription drugs, with requirements for licensed pharmacists to review and dispense prescriptions.
- 2023-08-21Beijing health authorities released a draft rule planning to ban AI-generated online medical prescriptions.
- 2025-02-25Hunan province health authorities issued a statement strictly prohibiting the use of AI and other automated methods to generate prescriptions for online clinics.
- 2026-05-25China's top drug regulator issued new guidelines explicitly banning AI from conducting pharmacist reviews of prescriptions and prohibiting prescription reuse.
Sources (13)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
Weekly AI Recap
Read this week's curated digest of top AI events →
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 虎嗅 ↗
This is a summary, not the original. Read the source, or get the weekly briefing.
The weekly digest
One email a week. Unsubscribe anytime.